Literature DB >> 27521441

Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Andre C Kalil1, Mark L Metersky2, Michael Klompas3, John Muscedere4, Daniel A Sweeney5, Lucy B Palmer6, Lena M Napolitano7, Naomi P O'Grady8, John G Bartlett9, Jordi Carratalà10, Ali A El Solh11, Santiago Ewig12, Paul D Fey13, Thomas M File14, Marcos I Restrepo15, Jason A Roberts16, Grant W Waterer17, Peggy Cruse18, Shandra L Knight18, Jan L Brozek19.   

Abstract

It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.These guidelines are intended for use by healthcare professionals who care for patients at risk for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), including specialists in infectious diseases, pulmonary diseases, critical care, and surgeons, anesthesiologists, hospitalists, and any clinicians and healthcare providers caring for hospitalized patients with nosocomial pneumonia. The panel's recommendations for the diagnosis and treatment of HAP and VAP are based upon evidence derived from topic-specific systematic literature reviews.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27521441      PMCID: PMC4981763          DOI: 10.1093/cid/ciw504

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  5 in total

1.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2005-02-15       Impact factor: 21.405

2.  In vitro activity of beta-lactam antimicrobial agents in combination with aztreonam tested against metallo-beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter baumannii.

Authors:  H S Sader; P R Rhomberg; R N Jones
Journal:  J Chemother       Date:  2005-12       Impact factor: 1.714

3.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

4.  Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.

Authors:  Roger L Nation; Jian Li; Otto Cars; William Couet; Michael N Dudley; Keith S Kaye; Johan W Mouton; David L Paterson; Vincent H Tam; Ursula Theuretzbacher; Brian T Tsuji; John D Turnidge
Journal:  Lancet Infect Dis       Date:  2014-10-21       Impact factor: 25.071

5.  Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients.

Authors:  S M Garonzik; J Li; V Thamlikitkul; D L Paterson; S Shoham; J Jacob; F P Silveira; A Forrest; R L Nation
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

  5 in total
  82 in total

1.  Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.

Authors:  J C Bader; E A Lakota; G E Dale; H S Sader; J H Rex; P G Ambrose; S M Bhavnani
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

Review 2.  The Lung Microbiome and Its Role in Pneumonia.

Authors:  Benjamin G Wu; Leopoldo N Segal
Journal:  Clin Chest Med       Date:  2018-12       Impact factor: 2.878

3.  Personalized antibiotic dosing for the critically ill.

Authors:  Jason A Roberts; Claire Roger; Jan J De Waele
Journal:  Intensive Care Med       Date:  2019-01-14       Impact factor: 17.440

4.  Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.

Authors:  Helio S Sader; Mariana Castanheira; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 5.  Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development.

Authors:  Sherwin K B Sy; Luning Zhuang; Serubbabel Sy; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2019-05       Impact factor: 6.447

6.  Procalcitonin in the Assessment of Ventilator Associated Pneumonia: A Systematic Review.

Authors:  Francesco Alessandri; Francesco Pugliese; Silvia Angeletti; Massimo Ciccozzi; Alessandro Russo; Claudio M Mastroianni; Gabriella d'Ettorre; Mario Venditti; Giancarlo Ceccarelli
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Treatment Trends and Outcomes in Healthcare-Associated Pneumonia.

Authors:  Sarah Haessler; Tara Lagu; Peter K Lindenauer; Daniel J Skiest; Aruna Priya; Penelope S Pekow; Marya D Zilberberg; Thomas L Higgins; Michael B Rothberg
Journal:  J Hosp Med       Date:  2017-11       Impact factor: 2.960

8.  Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae.

Authors:  Safa S Almarzoky Abuhussain; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

Review 9.  The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship.

Authors:  Marin H Kollef; Matteo Bassetti; Bruno Francois; Jason Burnham; George Dimopoulos; Jose Garnacho-Montero; Jeffrey Lipman; Charles-Edouard Luyt; David P Nicolau; Maarten J Postma; Antonio Torres; Tobias Welte; Richard G Wunderink
Journal:  Intensive Care Med       Date:  2017-02-04       Impact factor: 17.440

10.  Shorter Versus Longer Courses of Antibiotics for Infection in Hospitalized Patients: A Systematic Review and Meta-Analysis.

Authors:  Stephanie Royer; Kimberley M DeMerle; Robert P Dickson; Hallie C Prescott
Journal:  J Hosp Med       Date:  2018-01-25       Impact factor: 2.960

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.